Delpacibart braxlosiran

Delpacibart braxlosiran (Del-brax), an antibody oligonucleotide conjugate (AOC), consists of a monoclonal antibody (Delpacibart) (HY-P990051) that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DUX4 (Double homeobox protein) mRNA. It is used for the study of Facioscapulohumeral Muscular Dystrophy (FSHD) . The abnormal expression of DUX4 protein leads to changes in gene expression in muscle cells that are associated with the life-long, progressive loss of muscle function in patients with FSHD[1].

Product Specifications

CAS Number

[2929261-85-6]

Product Name Alternative

Del-brax; AOC 1020

UNSPSC

12352005

Target

Antibody-Oligonucleotide Conjugates (AOCs) ; Transferrin Receptor

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

[Delpacibartbraxlosiran]

References & Citations

[1]Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use. WO2025177244A1|[2]WHO Drug Information - Volume 39, No. 1, 2025